BioTech Capital Limited’s (ASX:BTC) wholly owned subsidiary BioImpact has extended its exclusive license and supply agreement with RLS Global AB to include two additional products.
BioTech is in the business of providing development capital and management expertise to high-growth Australian biotech, medtech and pharmaceutical companies.
RLS Global is a Swedish medtech company that develops and sells biochemical products and methods for the treatment of some of the world’s most common diseases.
BioImpact has won the rights to distribute RLS Global’s two dental products Perisolv and Carisolv within Australia, New Zealand and select countries across the Asia Pacific region.
Perisolv is a patented and biochemically active gel that optimises the dental professional’s treatment of advanced gum disorders like periodontitis, mucositis and peri-implantitis.
The gel when applied directly exerts a bacteriostatic effect and aids in dissolving degenerated tissue, making the debridement easier for both dental professionals and patients.
Carisolv is a patented gel that assists in the removal and treatment of dental caries. It is a minimally invasive treatment that gives better bonding strength to the filling.
Perisolv and Carisolv are classified as medical devices to be made available in Australia this financial year post inclusion in the Australian Register of Therapeutic Goods.
BioTech’s shares were last trading 11% higher intra-day, at $0.20.